Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration

Study of PRN and Every 2months Intravitreal Aflibercept After 3 Initial Monthly Injection for Age Related Macular Degeneration

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01824225

Enrollment

100

Registered

2013-04-04

Start date

2013-03-31

Completion date

2015-03-31

Last updated

2015-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related Macular Degeneration

Keywords

aflibercept, intravitreal injection

Brief summary

Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial monthly intravitreal aflibercept for the Japanese age related macular degeneration.

Interventions

DRUGAflibercept

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of age-related macular degeneration

Exclusion criteria

* Any treatment before intravitreal Aflibercept for age-related macular degeneration. * Visual acuity above 0.1 in decimal visual acuity

Design outcomes

Primary

Measure	Time frame
Visual acuity after treatment by PRN or 2 months intravitreal Aflibercept	one year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026